BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16848746)

  • 1. New substrate analogue inhibitors of factor Xa containing 4-amidinobenzylamide as P1 residue: part 1.
    Schweinitz A; Stürzebecher A; Stürzebecher U; Schuster O; Stürzebecher J; Steinmetzer T
    Med Chem; 2006 Jul; 2(4):349-61. PubMed ID: 16848746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly potent and selective substrate analogue factor Xa inhibitors containing D-homophenylalanine analogues as P3 residue: part 2.
    Stürzebecher A; Dönnecke D; Schweinitz A; Schuster O; Steinmetzer P; Stürzebecher U; Kotthaus J; Clement B; Stürzebecher J; Steinmetzer T
    ChemMedChem; 2007 Jul; 2(7):1043-53. PubMed ID: 17541992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism of inhibition and comparison with therapeutic heparins.
    Rezaie AR
    Thromb Haemost; 2003 Jan; 89(1):112-21. PubMed ID: 12540961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding.
    Hu X; Xiao Y; Yu C; Zuo Y; Yang W; Wang X; Gu B; Li J
    Eur J Pharmacol; 2018 Apr; 825():85-91. PubMed ID: 29475063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation.
    Wang W; Yuan J; Fu X; Meng F; Zhang S; Xu W; Xu Y; Huang C
    Molecules; 2016 Apr; 21(4):491. PubMed ID: 27089317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor.
    Hara T; Yokoyama A; Morishima Y; Kunitada S
    Thromb Res; 1995 Oct; 80(1):99-104. PubMed ID: 8578544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design of potent, amidine-derived inhibitors of factor Xa: evaluation of selectivity, anticoagulant activity, and antithrombotic activity.
    Wiley MR; Weir LC; Briggs S; Bryan NA; Buben J; Campbell C; Chirgadze NY; Conrad RC; Craft TJ; Ficorilli JV; Franciskovich JB; Froelich LL; Gifford-Moore DS; Goodson T; Herron DK; Klimkowski VJ; Kurz KD; Kyle JA; Masters JJ; Ratz AM; Milot G; Shuman RT; Smith T; Smith GF; Tebbe AL; Tinsley JM
    J Med Chem; 2000 Mar; 43(5):883-99. PubMed ID: 10715155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innovative Three-Step Microwave-Promoted Synthesis of
    Santana-Romo F; Lagos CF; Duarte Y; Castillo F; Moglie Y; Maestro MA; Charbe N; Zacconi FC
    Molecules; 2020 Jan; 25(3):. PubMed ID: 31979319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dibasic (amidinoaryl)propanoic acid derivatives as novel blood coagulation factor Xa inhibitors.
    Nagahara T; Yokoyama Y; Inamura K; Katakura S; Komoriya S; Yamaguchi H; Hara T; Iwamoto M
    J Med Chem; 1994 Apr; 37(8):1200-7. PubMed ID: 8164262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and structure-activity relationship of oxazolidinone derivatives containing novel S4 ligand as FXa inhibitors.
    Zhao Y; Jiang M; Zhou S; Wu S; Zhang X; Ma L; Zhang K; Gong P
    Eur J Med Chem; 2015; 96():369-80. PubMed ID: 25911624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and biological activity of novel tetrahydropyrazolopyridone derivatives as FXa inhibitors with potent anticoagulant activity.
    Sun X; Hong Z; Liu M; Guo S; Yang D; Wang Y; Lan T; Gao L; Qi H; Gong P; Liu Y
    Bioorg Med Chem; 2017 May; 25(10):2800-2810. PubMed ID: 28389110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a.
    Graff J; Picard-Willems B; Harder S
    Int J Clin Pharmacol Ther; 2007 Apr; 45(4):237-43. PubMed ID: 17474542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and biological activity of amidinobicyclic compounds (derivatives of DX-9065a) as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
    Komoriya S; Kanaya N; Nagahara T; Yokoyama A; Inamura K; Yokoyama Y; Katakura S; Hara T
    Bioorg Med Chem; 2004 May; 12(9):2099-114. PubMed ID: 15080912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa.
    Hara T; Yokoyama A; Ishihara H; Yokoyama Y; Nagahara T; Iwamoto M
    Thromb Haemost; 1994 Mar; 71(3):314-9. PubMed ID: 8029795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From selective substrate analogue factor Xa inhibitors to dual inhibitors of thrombin and factor Xa. Part 3.
    Dönnecke D; Schweinitz A; Stürzebecher A; Steinmetzer P; Schuster M; Stürzebecher U; Nicklisch S; Stürzebecher J; Steinmetzer T
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3322-9. PubMed ID: 17462889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Structure Based Study of Selective Inhibition of Factor IXa over Factor Xa.
    Kundu S; Wu S
    Molecules; 2021 Sep; 26(17):. PubMed ID: 34500804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles.
    Furugohri T; Isobe K; Honda Y; Kamisato-Matsumoto C; Sugiyama N; Nagahara T; Morishima Y; Shibano T
    J Thromb Haemost; 2008 Sep; 6(9):1542-9. PubMed ID: 18624979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticoagulant activity of a sulfated galactan: serpin-independent effect and specific interaction with factor Xa.
    Glauser BF; Rezende RM; Melo FR; Pereira MS; Francischetti IM; Monteiro RQ; Rezaie AR; Mourão PA
    Thromb Haemost; 2009 Dec; 102(6):1183-93. PubMed ID: 19967150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proposed cation-pi mediated binding by factor Xa: a novel enzymatic mechanism for molecular recognition.
    Lin Z; Johnson ME
    FEBS Lett; 1995 Aug; 370(1-2):1-5. PubMed ID: 7649284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa.
    Willardsen JA; Dudley DA; Cody WL; Chi L; McClanahan TB; Mertz TE; Potoczak RE; Narasimhan LS; Holland DR; Rapundalo ST; Edmunds JJ
    J Med Chem; 2004 Jul; 47(16):4089-99. PubMed ID: 15267248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.